Fibroblast Activation Protein Inhibitor (FAPI) PET Imaging in Sarcomas: A New Frontier in Nuclear Medicine

被引:4
|
作者
Giammarile, Francesco [1 ]
Knoll, Peter [1 ]
Paez, Diana [1 ]
Lobato, Enrique Estrada [1 ]
Teran, Adriana K. Calapaqui [2 ,3 ]
Bolton, Roberto C. Delgado [4 ,5 ,6 ]
机构
[1] IAEA, Dept Nucl Sci & Applicat, Nucl Med & Diagnost Imaging Sect, Vienna, Austria
[2] Univ Hosp Marques de Valdecilla, Dept Pathol, Santander, Spain
[3] Inst Invest Sanitaria Valdecilla IDIVAL, Santander, Spain
[4] Univ Hosp San Pedro, Dept Diagnost Imaging Radiol & Nucl Med, Logrono, La Rioja, Spain
[5] Ctr Biomed Res La Rioja CIBIR, Logrono, La Rioja, Spain
[6] Serv Cantabro Salud, Santander, Spain
关键词
D O I
10.1053/j.semnuclmed.2024.01.001
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The field of nuclear medicine has witnessed significant advancements in recent years, particularly in the area of PET imaging. One such development is the use of Fibroblast Activation Protein Inhibitors (FAPI) as a novel radiotracer. FAPI PET imaging has shown promising results in various malignancies, including sarcomas, which are a diverse group of cancers originating from mesenchymal cells. This paper aims to explore the potential of FAPI PET imaging in the diagnosis, staging, and treatment monitoring of sarcomas. Several studies have demonstrated the potential of FAPI PET in sarcomas. Furthermore, FAPI PET imaging has shown potential in assessing treatment response, with changes in FAPI uptake correlating with treatment outcomes. However, there are challenges to be addressed. The heterogeneity of sarcomas, both inter- and intra-tumoral, may affect the uniformity of Fibroblast Activation Protein (FAP) expression and thus the effectiveness of FAPI PET imaging. Additionally, the optimal timing and dosage of FAPI for PET imaging in sarcomas need further investigation. In conclusion, the introduction of FAPI PET imaging represents a significant advancement in the field of nuclear medicine and oncology. The ability to target FAP, a protein overexpressed in the majority of sarcomas, offers new possibilities for the diagnosis and treatment of these complex and diverse tumors. Its potential applications in diagnosis, staging, and theranostics are vast, and on -going research continues to explore and address its limitations. As we continue to deepen our understanding of this novel imaging technique, it is hoped that FAPI PET imaging will play an increasingly important role in the fight against cancer. However, as with any new technology, further research is needed to fully understand the potential and limitations of FAPI PET imaging in the clinical setting. Semin Nucl Med 54:340-344 (c) 2024 Elsevier Inc. All rights reserved.
引用
收藏
页码:340 / 344
页数:5
相关论文
共 50 条
  • [1] Fibroblast Activation Protein Inhibitor (FAPI)-PET Imaging in Sarcoma
    Kessler, Lukas
    PET CLINICS, 2023, 18 (03) : 353 - 359
  • [2] FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease
    Mori, Yuriko
    Dendl, Katharina
    Cardinale, Jens
    Kratochwil, Clemens
    Giesel, Frederik L.
    Haberkorn, Uwe
    RADIOLOGY, 2023, 306 (02)
  • [3] FAPI-PET/CT (Fibroblast Activation Protein Inhibitor) in Staging of Pancreatic Cancer
    Kratochwil, C.
    Lindner, T.
    Giesel, F. L.
    Loktev, A.
    Mier, W.
    Lang, M.
    Haberkorn, U.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S97 - S98
  • [4] Fibroblast activation in sarcoidosis as assessed by 68Ga-FAPI (fibroblast activation protein inhibitor)-46 PET/CT
    O'Brien, S.
    Musameh, K.
    El Obeid, M.
    Butler, T.
    Armstrong, M.
    Cunningham, Z.
    Atzinger, A.
    Kuwert, T.
    Mitchell, P. D.
    Donnelly, S. C.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2024, 117 (08)
  • [5] Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET)
    Yuriko Mori
    Emil Novruzov
    Dominik Schmitt
    Jens Cardinale
    Tadashi Watabe
    Peter L. Choyke
    Abass Alavi
    Uwe Haberkorn
    Frederik L. Giesel
    npj Imaging, 2 (1):
  • [6] Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer
    Strating, Esther
    van de Loo, Anne
    Elias, Sjoerd
    Lam, Marnix
    Kranenburg, Onno
    PET CLINICS, 2023, 18 (03) : 325 - 335
  • [7] Fibroblast Activation Protein Inhibitor PET Imaging in Head and Neck Cancer
    Roehrich, Manuel
    PET CLINICS, 2023, 18 (03) : 315 - 323
  • [8] Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers
    M. Syed
    P. Flechsig
    J. Liermann
    P. Windisch
    F. Staudinger
    S. Akbaba
    S. A. Koerber
    C. Freudlsperger
    P. K. Plinkert
    J. Debus
    F. Giesel
    U. Haberkorn
    S. Adeberg
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 2836 - 2845
  • [9] Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers
    Syed, M.
    Flechsig, P.
    Liermann, J.
    Windisch, P.
    Staudinger, F.
    Akbaba, S.
    Koerber, S. A.
    Freudlsperger, C.
    Plinkert, P. K.
    Debus, J.
    Giesel, F.
    Haberkorn, U.
    Adeberg, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (12) : 2836 - 2845
  • [10] The Superiority of Fibroblast Activation Protein Inhibitor (FAPI) PET/CT Versus FDG PET/CT in the Diagnosis of Various Malignancies
    Dong, Yanzhao
    Zhou, Haiying
    Alhaskawi, Ahmad
    Wang, Zewei
    Lai, Jingtian
    Yao, Chengjun
    Liu, Zhenfeng
    Ezzi, Sohaib Hasan Abdullah
    Kota, Vishnu Goutham
    Abdulla, Mohamed Hasan Abdulla Hasan
    Lu, Hui
    CANCERS, 2023, 15 (04)